We are N1-Methyl-4-nitrobenzene-1,2-diamine CAS:41939-61-1 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: N1-Methyl-4-nitrobenzene-1,2-diamine
Physical and Chemical Properties:
Density: 1.358g / cm3
Boiling point: 366.8ºC at 760 mmHg
Melting point: 174-176ºC
Flash point: 175.6ºC
Refractive index: 1.682
Appearance: red powder
25kg cardboard drum or according to customer specified requirements
Storage:Refrigerator.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Bendamustine hydrochloride CAS:3543-75-7
Intermediates of Bendamustine CAS:16506-27-7
Related News: With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs.azetidin-3-ona, hidrocloruro CAS:17557-84-5 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.N-benzyl-2-(2-methoxyphenoxy)ethanamine “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.methyl 2-bromo-3-[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]propanoate CAS:105355-25-7 Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).